Diphosphate Mimetics Inhibit OGT Kinases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting glycosyltransferases, particularly O-linked N-acetylglucosamine transferase (OGT) and protein kinases, face challenges due to the difficulty in designing effective inhibitors that can selectively target these enzymes without interfering with cellular substrates, and existing inhibitors often fail to penetrate cells or exhibit weak binding affinity.
Innovation Solution
Development of compounds of Formula (I), which include dicarbamate and dithiocarbamate structures that act as neutral diphosphate mimics, capable of inhibiting OGT and kinases by reacting with essential active site lysines and nearby cysteines, thereby inhibiting enzyme activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors are designed to target OGT and kinases, then enzyme inhibition activity is improved, but cell penetration capability deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of diphosphate mimics, specifically adjusting charge distribution and molecular properties to enable cell penetration while maintaining enzyme inhibition. The compounds transform from highly charged structures that cannot cross membranes to neutral or less charged structures that can penetrate cells but still bind to target enzymes through optimized functional groups and molecular architecture.
2Reliability
If inhibitors are designed with high binding affinity to OGT, then inhibition effectiveness is improved, but selectivity against cellular substrates deteriorates
Solution Approach 1:
The patent applies local quality by creating inhibitors with differentiated binding interactions: strong local interactions (hydrogen bonding, electrostatic interactions) at the active site for high affinity, while maintaining overall molecular neutrality to avoid non-specific binding. This localized optimization of binding properties enables both high effectiveness and selectivity.
Solution Approach 2:
The patent uses diphosphate mimic structures as intermediaries that bridge the gap between natural substrates and inhibitor design. These mimics retain key recognition features for the enzyme active site while lacking the reactive portions that would cause non-specific binding, thereby achieving selective inhibition.
3Reliability
If diphosphate groups are retained in inhibitor structure, then binding affinity to OGT is improved, but cellular uptake deteriorates
Solution Approach 1:
The patent applies taking out by extracting the essential binding features of diphosphate groups (charge distribution, geometric arrangement) while removing the highly charged phosphate moieties themselves. The inhibitors incorporate alternative functional groups that mimic the electrostatic and hydrogen bonding properties of diphosphates without the membrane-permeation barrier.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit OGT and kinases, offering potential therapeutic benefits for conditions such as proliferative diseases, neurodegenerative diseases, diabetes, and inflammatory diseases by reducing O-GlcNAcylation and kinase activity, and can be used both in vitro and in vivo.
Implementation Method 1
capable of inhibiting OGT and kinases by reacting with essential active site lysines and nearby cysteines
Data Source
AI summary
The present invention provides compounds of Formulae (I)-(V), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In one aspect, compounds of the present invention are useful as glycosyltransferase inhibitors, in particular, O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) inhibitors. In another aspect, compounds of the present invention are useful as kinase inhibitors, in particular, PLK1 inhibitors, GSK3P inhibitors, or MAPKAPK2 inhibitors. The present invention further provides methods of using the inventive compounds, e.g., as biological probes to study the inhibition of OGT and/or kinase activity and as therapeutics, e.g., for the treatment of OGT-associated and/or kinase-associated conditions.